We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+15.42%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$324M
AUM Growth
+$11.9M
Cap. Flow
-$17.7M
Cap. Flow %
-5.47%
Top 10 Hldgs %
51.2%
Holding
69
New
3
Increased
9
Reduced
7
Closed
6
Avg Time Held
1.8 years
Top 10 Avg Time Held
0.3 years
Top 20 Avg Time Held
0.4 years

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.99M
2
PTCT icon
PTC Therapeutics
PTCT
+$5.11M
3
ILMN icon
Illumina
ILMN
+$4.58M
4
TVTX icon
Travere Therapeutics
TVTX
+$4.09M
5
AZN icon
AstraZeneca
AZN
+$4.08M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$11.6M
3
BIIB icon
Biogen
BIIB
+$6.81M
4
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$5.25M
5
INCY icon
Incyte
INCY
+$4.59M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$35.8M 11.07%
314,973
-140,000
-31% -$11.6M
2016 Q4
24 quarters
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$21.4M 6.6%
166,200
– –
2017 Q1
23 quarters
INCY icon
3
Incyte
INCY
$23B
$18.4M 5.68%
229,000
-60,000
-21% -$4.59M
2016 Q4
24 quarters
ALKS icon
4
Alkermes
ALKS
$6.85B
$15.5M 4.78%
593,000
– –
2022 Q2
2 quarters
HRMY icon
5
Harmony Biosciences
HRMY
$2.22B
$14.6M 4.5%
264,500
– –
2021 Q2
6 quarters
QURE icon
6
uniQure
QURE
$1.52B
$14.3M 4.42%
631,500
+87,000
+16% +$1.88M
2019 Q2
14 quarters
SUPN icon
7
Supernus Pharmaceuticals
SUPN
$2.23B
$13.7M 4.22%
383,500
+86,000
+29% +$2.99M
2021 Q2
6 quarters
ITCI icon
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.7M 3.62%
221,856
– –
2020 Q1
11 quarters
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11.1M 3.41%
244,000
+108,000
+79% +$6.99M
2019 Q1
15 quarters
ILMN icon
10
Illumina
ILMN
$39.5B
$9.4M 2.9%
47,802
+22,102
+86% +$4.58M
2021 Q3
5 quarters
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$31.5B
$9.02M 2.79%
38,000
– –
2017 Q3
21 quarters
KDNY
12
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$8.91M 2.75%
340,389
– –
2021 Q2
6 quarters
EXEL icon
13
Exelixis
EXEL
$15.4B
$8.71M 2.69%
543,000
– –
2022 Q2
2 quarters
REGN icon
14
Regeneron Pharmaceuticals
REGN
$82B
$8.08M 2.5%
11,200
– –
2020 Q2
10 quarters
RARE icon
15
Ultragenyx Pharmaceutical
RARE
$1.45B
$8.06M 2.49%
174,052
– –
2021 Q1
7 quarters
TVTX icon
16
Travere Therapeutics
TVTX
$4.68B
$7.96M 2.46%
379,019
+193,000
+104% +$4.09M
2020 Q4
8 quarters
DYN icon
17
Dyne Therapeutics
DYN
$2.68B
$7.42M 2.29%
641,068
+291,000
+83% +$3.37M
2021 Q1
7 quarters
SNY icon
18
Sanofi
SNY
$96.7B
$6.94M 2.14%
143,500
– –
2022 Q1
3 quarters
BIIB icon
19
Biogen
BIIB
$34.8B
$5.92M 1.83%
21,400
-24,100
-53% -$6.81M
2022 Q2
2 quarters
PTCT icon
20
PTC Therapeutics
PTCT
$4.94B
$5.49M 1.7%
144,000
+123,000
+586% +$5.11M
2019 Q1
15 quarters
VERA icon
21
Vera Therapeutics
VERA
$1.99B
$5.43M 1.68%
281,257
– –
2021 Q4
4 quarters
GILD icon
22
Gilead Sciences
GILD
$194B
$4.94M 1.53%
57,584
-151,200
-72% -$12M
2016 Q4
24 quarters
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$10.7B
$4.51M 1.39%
43,656
-15,000
-26% -$1.41M
2016 Q4
24 quarters
AZN icon
24
AstraZeneca
AZN
$258B
$4.41M 1.36%
+32,500
New +$4.08M
2022 Q4
0 quarters
AMGN icon
25
Amgen
AMGN
$236B
$4.27M 1.32%
16,246
– –
2018 Q4
16 quarters
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2022 Portfolio in Review

As of Q4 2022, International Biotechnology Trust held 69 positions worth $324M, up 3.8% from $312M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

International Biotechnology Trust withdrew a net $17.7M in Q4 2022, closing 6 positions and reducing 7 holdings. Its most notable exit was Lakefront Biotherapeutics American Depositary Shares, an estimated $5.25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, International Biotechnology Trust opened a new position in AstraZeneca worth $4.41M.

  • International Biotechnology Trust's largest Q4 2022 buy was AstraZeneca: 32,500 shares worth $4.41M.
  • International Biotechnology Trust added most to Mirati Therapeutics, Inc. Common Stock in Q4 2022, an estimated $6.99M increase.
  • International Biotechnology Trust's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $12M.
  • International Biotechnology Trust fully exited Lakefront Biotherapeutics American Depositary Shares in Q4 2022, selling an estimated $5.25M.
  • International Biotechnology Trust's ten largest holdings make up 51% of its $324M portfolio in Q4 2022.
  • International Biotechnology Trust opened 3 new positions and closed 6 in Q4 2022.
  • International Biotechnology Trust's portfolio value rose 3.8% quarter-over-quarter to $324M.

Based on International Biotechnology Trust's 13F filing for Q4 2022, filed 1 Feb 2023.